Want to see HYPMY full AI Analyst Report?
Top Page
Hypera SA
(OTC:HYPMY)
Select Model
Select Model
Rating:77Outperform
Price Target:
$4.50
▲(5.39% Upside)
Action:Reiterated
Date:10/06/26
Overall score is driven by strong financial profitability and cash generation, reinforced by a positive earnings call featuring growth, margin expansion, and deleveraging progress plus meaningful product milestones. Valuation is also supportive (low P/E with a solid dividend yield). The main offset is technical stretch (RSI ~77.9), which raises near-term pullback risk despite an established uptrend.
Positive Factors
Strong and expanding profitability
Hypera is generating substantial profit across its branded healthcare portfolio, with strong gross, EBIT, EBITDA, and net margins. The latest period also showed margin expansion, indicating pricing, mix, and operating execution can support earnings power over the next several quarters.
Negative Factors
Meaningful remaining leverage
Although leverage is improving, debt remains material relative to operating earnings and management still needs further deleveraging. Continued debt service can constrain flexibility for acquisitions, buybacks, or higher distributions if operating conditions weaken or cash conversion becomes less consistent.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong and expanding profitability
Hypera is generating substantial profit across its branded healthcare portfolio, with strong gross, EBIT, EBITDA, and net margins. The latest period also showed margin expansion, indicating pricing, mix, and operating execution can support earnings power over the next several quarters.
Read all positive factors
Hypera SA (HYPMY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.69B
Dividend Yield7.01%
Average Volume (3M)4.36K
Price to Earnings (P/E)7.7
Beta (1Y)0.61
Revenue Growth42.81%
EPS Growth142.52%
CountryUS
Employees10,564
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)2.68
Shares Outstanding704,009,030
10 Day Avg. Volume0
30 Day Avg. Volume4,355
Financial Highlights & Ratios
PEG Ratio-1.11
Price to Book (P/B)1.15
Price to Sales (P/S)1.86
P/FCF Ratio8.08
Enterprise Value/Market Cap1.49
Enterprise Value/Revenue0.46
Enterprise Value/Gross Profit0.75
Enterprise Value/Ebitda1.37
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hypera SA Business Overview & Revenue Model
Company Description
Hypera S.A. is a prominent pharmaceutical enterprise primarily operating within Brazil. The company maintains a diverse product portfolio that includes a vast array of prescription medications, marketed under numerous brand names such as Adacne, A...
How the Company Makes Money
Hypera makes money primarily by selling healthcare products in Brazil, generating revenue from the commercial sale of its portfolio to pharmacies, drugstore chains, distributors, and other retail channels. Its key revenue streams come from (1) bra...
Hypera SA Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Feb 19, 2027
Earnings Call Sentiment Positive
The call delivered a predominantly positive message: the company reported solid top-line growth (net revenue +8.5%, sell-out +7.6%), margin expansion (gross margin 61.8%), strong EBITDA (BRL 755m) and cash generation (operating cash flow BRL 819m, free cash flow BRL 638m), alongside strategic approvals and partnerships (Semavy ANVISA approval; patented menopausal treatment). Structural working capital improvements and a meaningful reduction in net debt support financial resilience. Near-term challenges include elevated marketing and CapEx, remaining leverage (2.1x LTM EBITDA), competition and informal channels in the GLP-1 market, and potential temporary inventory build for product launches. Overall, the positives — growth, margin expansion, robust cash flow, product approvals and strategic partnerships — materially outweigh the manageable near-term headwinds.Positive Updates
Revenue and Sell-Out Growth
Net revenue grew 8.5% year-over-year to BRL 2.34 billion, driven by a 7.6% sell-out increase. New product launches over the past 12 months contributed 2.2 percentage points to sell-out growth.
Negative Updates
Elevated Marketing and Launch-Related Spending
Marketing expenses increased 13.7% year-over-year to BRL 411 million due to expanded point-of-sale initiatives and growth of the medical sales team to support prescription product launches.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue and Sell-Out Growth
Net revenue grew 8.5% year-over-year to BRL 2.34 billion, driven by a 7.6% sell-out increase. New product launches over the past 12 months contributed 2.2 percentage points to sell-out growth.
Read all positive updates
Company Guidance
Guidance from the call emphasized continued top‑line and margin momentum and disciplined balance‑sheet repair: management expects continued sell‑out strength (7.6% Q2) and net revenue growth (8.5% in Q2; revenue BRL 2.34bn) aided by new launches (contributed +2.2 p.p. to sell‑out) and target‑market growth (6.2%), with volume up ~5%; gross margin improvement (61.8%, +1.7 p.p. YoY) and gross profit +11.5% should support EBITDA of BRL 755m (32.3% margin) and further cash conversion after Q2 operating cash flow of BRL 819m (108.5% of EBITDA) and free cash flow BRL 638m. They reiterated structural working‑capital gains (inventories and WC now ~28% of quarter‑annualized revenue and expected to improve slightly), a high 2026 CapEx run‑rate tied to plant expansions before stepping down after 2027/2028, and near‑term commercial milestones: ANVISA approval for semaglutide (addressing a BRL 15bn GLP‑1 market) with launch/sales expected within months (pricing cleared by CMED) and a non‑hormonal menopausal treatment (patent to 2034) slated for early next year; financial targets include continued net‑debt reduction from BRL 5.9bn (2.1x LTM EBITDA) toward ~1.5x EBITDA before considering M&A, buybacks or higher shareholder distributions.Hypera SA Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
71
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.78B | 7.70B | 7.44B | 7.91B | 7.55B | 5.94B |
| Gross Profit | 5.32B | 4.55B | 4.38B | 5.00B | 4.76B | 3.80B |
| EBITDA | 2.93B | 2.26B | 2.23B | 2.88B | 2.77B | 2.16B |
| Net Income | 1.74B | 1.20B | 1.34B | 1.65B | 1.70B | 1.33B |
Balance Sheet | ||||||
| Total Assets | 25.35B | 25.16B | 24.56B | 24.51B | 23.76B | 19.82B |
| Cash, Cash Equivalents and Short-Term Investments | 1.58B | 1.65B | 1.74B | 2.58B | 2.86B | 2.29B |
| Total Debt | 7.48B | 9.34B | 9.40B | 9.96B | 9.68B | 7.41B |
| Total Liabilities | 10.92B | 12.63B | 12.46B | 12.99B | 13.10B | 9.98B |
| Stockholders Equity | 14.43B | 12.52B | 12.10B | 11.50B | 10.65B | 9.83B |
Cash Flow | ||||||
| Free Cash Flow | 1.90B | 1.78B | 1.77B | 1.58B | 529.34M | 560.25M |
| Operating Cash Flow | 2.41B | 2.57B | 2.54B | 2.40B | 2.04B | 1.40B |
| Investing Cash Flow | -544.32M | -689.50M | -592.44M | -791.19M | -1.74B | -4.41B |
| Financing Cash Flow | -1.50B | -1.98B | -2.79B | -1.89B | 278.95M | 557.06M |
Hypera SA Technical Analysis
Negative
4.27
Price Trends
4.66
Negative
4.36
Negative
4.37
Negative
Market Momentum
0.05
Positive
28.92
Positive
48.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPMY, the sentiment is Negative. The current price of 4.27 is below the 20-day moving average (MA) of 5.10, below the 50-day MA of 4.66, and below the 200-day MA of 4.37, indicating a bearish trend. The MACD of 0.05 indicates Positive momentum. The RSI at 28.92 is Positive, neither overbought nor oversold. The STOCH value of 48.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HYPMY.
Hypera SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $2.69B | 7.67 | 13.10% | 7.01% | 42.81% | 142.52% | |
67 Neutral | $11.42B | 39.01 | 7.37% | 0.61% | -10.52% | -55.45% | |
67 Neutral | $44.61B | 20.96 | 9.89% | 1.22% | 4.99% | 12.37% | |
60 Neutral | $21.01B | -50.81 | -2.79% | 2.62% | 4.92% | 87.81% | |
58 Neutral | $6.71B | 42.25 | -326.75% | ― | 9.28% | 4917.17% | |
54 Neutral | $2.20B | -1.27 | -55.97% | 7.33% | -4.18% | -2138.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HYPMY
Hypera SA
4.04
-0.15
-3.54%
RDY
Dr Reddy's Laboratories
13.75
-0.77
-5.30%
VTRS
Viatris
18.72
8.78
88.39%
PRGO
Perrigo Company
16.02
-3.72
-18.84%
AMRX
Amneal Pharmaceuticals
21.44
11.15
108.36%
HLN
Haleon PLC Sponsored ADR
10.08
1.13
12.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.